Silexion Therapeutics Prepares for Key Industry Conference
Silexion Therapeutics Corp. is gearing up to make a significant impression at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, also known as NobleCon21. This clinical-stage biotechnology organization specializes in oncology and has set out to showcase their compelling developments in cancer treatment.
Details of the Presentation
During NobleCon21, Silexion's leadership team will deliver a comprehensive presentation that dives into their pioneering approaches to oncology. The presentation is scheduled for December 3, with insights shared from key company figures, including Ilan Hadar, the Chief Executive Officer, and Mirit Horenshtein-Hadar, the Chief Financial Officer.
Schedule and Format
The scheduled timeslot for the presentation is from 2:30 to 2:55 PM ET. Attendees can expect to learn about Silexion's clinical trials, innovative treatments, and future directions. Following the main event, the management will also be available for individual meetings, establishing opportunities for deeper discussions.
Post-Conference Opportunities
Interested investors and stakeholders will be able to access a replay of the presentation via Silexion’s investor relations webpage after the event. This ensures that anyone who could not attend the live presentation will have the chance to catch up on the key insights and announcements made.
A Closer Look at Silexion's Innovations
As a leader in the biopharmaceutical sector, Silexion Therapeutics focuses on addressing pressing needs within oncology, particularly for patients facing solid tumor cancers associated with the mutated KRAS oncogene. This genetic mutation plays a critical role in several cancer types and is a primary target for innovative therapies.
Recent Clinical Developments
Silexion’s recent Phase 2a clinical trial results have shown promising trends in efficacy when compared to standard chemotherapy treatments. The encouraging results signify a potential leap forward in the therapeutic landscape for patients suffering from locally advanced pancreatic cancer, where options are typically limited.
Commitment to Advancements in Oncology
Silexion is steadfast in its mission to redefine treatment protocols for difficult-to-treat cancers. Their commitment not only lies in clinical trials but also in pushing the boundaries of what is possible in oncology. They are focused on developing their lead product candidate, which aims to provide advanced solutions for patients with unmet medical needs.
Company Contact Information
Silexion Therapeutics encourages interested parties to reach out with questions or for more information. You can contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
Email: mirit@silexion.com
For Investor Queries:
Arx Investor Relations
North American Equities Desk
Email: silexion@arxhq.com
Chuck Padala
LifeSci Advisors
Email: Chuck@lifesciadvisors.com
Frequently Asked Questions
What is the main focus of Silexion Therapeutics?
Silexion Therapeutics specializes in developing innovative treatments for solid tumors, especially those related to the mutated KRAS oncogene.
When will Silexion present at NobleCon21?
The presentation is scheduled for December 3, from 2:30 to 2:55 PM ET.
Who will be speaking at the event?
Ilane Hadar, the CEO, and Mirit Horenshtein-Hadar, the CFO, will represent Silexion at the conference.
How can I access the presentation after the event?
A replay of the presentation will be available on Silexion’s investor relations website post-conference.
What recent trial results has Silexion achieved?
Silexion’s Phase 2a clinical trials have shown a favorable trend in outcomes compared to standard chemotherapy.
